|
| Index | - | P/E | - | EPS (ttm) | -0.31 | Insider Own | 3.60% | Shs Outstand | 10.52M | Perf Week | 16.93% |
| Market Cap | 44.55M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | 6.82M | Perf Month | -1.00% |
| Income | -3.30M | PEG | - | EPS next Q | - | Inst Own | 12.20% | Short Float | 3.53% | Perf Quarter | 158.26% |
| Sales | - | P/S | - | EPS this Y | -44.50% | Inst Trans | 31.37% | Short Ratio | 0.05 | Perf Half Y | -82.77% |
| Book/sh | -0.19 | P/B | - | EPS next Y | - | ROA | - | Target Price | - | Perf Year | -80.79% |
| Cash/sh | 0.01 | P/C | 222.75 | EPS next 5Y | - | ROE | - | 52W Range | 1.05 - 7.00 | Perf YTD | 182.86% |
| Dividend | - | P/FCF | - | EPS past 5Y | 53.40% | ROI | - | 52W High | -57.57% | Beta | - |
| Dividend % | - | Quick Ratio | 0.30 | Sales past 5Y | - | Gross Margin | - | 52W Low | 182.86% | ATR | 0.53 |
| Employees | - | Current Ratio | 0.30 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 55.42 | Volatility | 22.46% 17.93% |
| Optionable | No | Debt/Eq | - | EPS Q/Q | -136.00% | Profit Margin | - | Rel Volume | 4.39 | Prev Close | 2.67 |
| Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 5.22M | Price | 2.97 |
| Recom | - | SMA20 | 26.25% | SMA50 | -16.35% | SMA200 | -61.93% | Volume | 22,892,367 | Change | 11.24% |
 | ||||||||||
| ||||||||||
|
||||||||||
| ||||||||||
| Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York. | ||||||||||
| ||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite